Filing Flows › Biofrontera (BFRI) › R&D spending
Biofrontera (BFRI) R&D spending by quarter
Biofrontera's R&D spending was $448K in Q2 2026 (second quarter 2026), -50% from Q1 2026. Over the last 7 quarters it ranged from $448K (Q2 2026) to $1.2M (Q1 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $448K | -50% | -49% |
| Q1 2026 | $900K | +14% | -25% |
| Q4 2025 | $787K | -8% | +0.5% |
| Q3 2025 | $854K | -2% | — |
| Q2 2025 | $870K | -28% | — |
| Q1 2025 | $1.2M | +54% | — |
| Q4 2024 | $783K | — | — |
Q2 2026 at a glance
Biofrontera, Q2 2026: revenue $12.0M (+33% year over year), operating margin -4.4%, net loss $604K, operating cash flow −$1.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is Biofrontera's R&D spending?
Biofrontera's R&D spending was $448K in Q2 2026 (second quarter 2026), -50% from Q1 2026.
How has Biofrontera's R&D spending changed?
Over the last 7 quarters it ranged from $448K (Q2 2026) to $1.2M (Q1 2025).